Blood Stream Infection Testing Industry Growth Insights: Revenue Forecast to 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the blood stream infection testing market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Blood Stream Infection Testing Market?
The blood stream infection testing market has experienced substantial growth in its size over recent years. This market is anticipated to expand from $8.49 billion in 2025 to $9.5 billion in 2026, at a compound annual growth rate (CAGR) of 11.9%. The historical expansion can be attributed to a rising incidence of bloodstream infections, increasing rates of hospital-acquired infections, the enlargement of clinical microbiology laboratories, the adoption of automated diagnostic instruments, and growing awareness concerning sepsis management.
The blood stream infection testing market is projected to experience substantial expansion in the coming years. This market is forecast to reach $14.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. Key factors driving this growth during the projected period include a heightened need for swift diagnostic results, the increasing use of molecular diagnostics within healthcare facilities, the broadening scope of personalized infection management, greater financial commitments to sophisticated laboratory infrastructure, and the growing incorporation of AI-powered diagnostic instruments. Significant trends anticipated in the forecast timeframe encompass the wider acceptance of rapid molecular diagnostic assays, an increase in the deployment of automated blood culture systems, the enhanced incorporation of antimicrobial susceptibility testing, the proliferation of multiplex pathogen detection panels, and a heightened emphasis on the prompt diagnosis of sepsis.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20514&type=smp
What Drivers Are Supporting Technological Adoption In The Blood Stream Infection Testing Market?
The expanding occurrence of infectious diseases is anticipated to boost the blood stream infection testing market’s expansion in the future. These illnesses originate from disease-causing microorganisms like bacteria, viruses, fungi, or parasites. The incidence of infectious diseases is escalating due to various elements, including increased international travel, growing urban populations, shifts in climate, resistance to antibiotics, and inadequate vaccination coverage. Bloodstream infection testing plays a crucial role in managing infectious diseases by helping to diagnose and pinpoint the pathogens responsible for sepsis and other serious infections, thereby facilitating precise and effective therapeutic interventions. As an illustration, in October 2024, the World Health Organization, an international public health body located in Switzerland, reported that roughly 8.2 million individuals received a new tuberculosis diagnosis in 2023, an increase from around 7.5 million in 2022, establishing tuberculosis as the primary fatal infectious disease. Consequently, the rising prevalence of infectious diseases is stimulating the blood stream infection testing market.
What Segment Types Are Examined In The Blood Stream Infection Testing Market?
The blood stream infection testing market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Sample Type: Whole Blood, Blood Culture
3) By Technology: Polymerase Chain Reaction (PCR), Mass Spectroscopy, In Situ Hybridization, Other Technologies
4) By End-User: Hospitals And Diagnostic Centers, Laboratory Service Providers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Blood Culture Systems, Automated Microbial Identification Systems, Molecular Diagnostic Instruments
2) By Reagents And Consumables: Blood Culture Media, Antimicrobial Susceptibility Testing Reagents, Nucleic Acid Extraction Kits
3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services
What Long-Term Trends Are Expected To Shape The Future Of The Blood Stream Infection Testing Market?
Companies operating within the blood stream infection testing market are concentrating on integrating advanced technologies, such as host-response diagnostics powered by machine learning, to enhance rapid detection, improve clinical decision support, and potentially advance patient management. Host-response diagnostics work by analyzing a patient’s immune system through gene expression signatures in blood samples, utilizing artificial intelligence (AI)-derived algorithms to infer the presence, type, and probable severity of an infection in real time, thereby assisting clinicians in making quicker and more accurate treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, received clearance from the US Food and Drug Administration for TriVerity. This machine-learning-based molecular blood test is designed to aid in the swift evaluation of patients with suspected acute infections or sepsis, featuring the measurement of 29 immune-related mRNAs and AI-generated scores indicating the likelihood of bacterial infection, viral infection, and the risk of severe illness, with results intended to be available in roughly 30 minutes. TriVerity supports clinical decision making by reducing diagnostic uncertainty, assisting timely targeted therapy, and helping to optimize hospital resource utilization when utilized alongside standard clinical evaluation and laboratory findings.
Who Are The Top-Performing Companies In The Blood Stream Infection Testing Market In Recent Years?
Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Blood Stream Infection Testing Market?
North America was the largest region in the blood stream infection testing market in 2025. The regions covered in the blood stream infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Blood Stream Infection Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20514&type=smp
Browse Through More Reports Similar to the Global Blood Stream Infection Testing Market 2026, By The Business Research Company
Preoperative Infection Prevention And Wound Cleansing Devices Market Report 2026
Infection Control Supplies Market Report 2026
https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report
Urinary Tract Infection Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
